纽瑞特医疗完成8亿元D轮融资：“核素+核药”推动核医药产业链自主可控

Core Viewpoint - The article highlights the significant advancements made by Chengdu Nureter Medical Technology Co., Ltd. in the field of innovative nuclear medicine, particularly in the self-supply of key isotopes and the clinical transformation of innovative nuclear drugs, following a recent D-round financing of approximately 800 million RMB [1][3]. Group 1: Company Developments - Nureter Medical has established an internationally leading base for the research, production, and sales of medical isotopes and drugs, and is accelerating the localization of cutting-edge radioactive drugs through strategic partnerships with international pharmaceutical and medical device companies [3]. - The company has successfully developed several rare isotopes, including the self-innovated Gallium generator, which has not only gained a foothold in the domestic market but has also entered the Southeast Asian market, laying the groundwork for future overseas expansion [3]. - Nureter Medical has built China's first commercial 30MeV IKON proton accelerator, which is set to achieve the self-supply of over ten key isotopes, including Germanium [Ge] and Actinium [Ac] [3]. Group 2: Clinical Trials and Product Pipeline - The company has four research pipelines in clinical stages: NRT6003 injection for liver cancer is in Phase III trials; NRT6008 injection for pancreatic cancer is in Phase I/II trials; two radioactive drugs for solid tumors are in Phase I trials, having received clinical trial approvals in both China and the United States [3]. - Additionally, multiple research pipelines are in preclinical development stages, indicating a robust pipeline for future product offerings [3]. Group 3: Investment and Strategic Goals - The recent investment from Shenzhen Capital Group and China Life Capital aims to support the national strategy for the localization of innovative drugs and the civilian application of nuclear technology, further promoting breakthroughs in cancer treatment [5]. - The investment is expected to enhance the resilience of the national nuclear medicine supply chain, addressing the long-standing reliance on imports for medical isotopes [5][6]. - Nureter Medical's CFO stated that this financing marks a significant milestone in the company's development, facilitating the acceleration of innovative nuclear drug commercialization and the establishment of a key isotope industrialization capability [6].